Table of Contents
ISRN Ophthalmology
Volume 2012, Article ID 267643, 10 pages
Clinical Study

Triamcinolone and Bevacizumab as Adjunctive Therapies to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

1Ophthalmology Department, University Hospital Complex, Ramon Baltar s/n, 15706 Santiago de Compostela, Spain
2Gomez-Ulla Institute of Ophthalmology, Avenida de las Burgas 2, HNS de la Esperanza, 15705 Santiago de Compostela, Spain
3Ophthalmology Department, Bellvitge University Hospital, Avenida Granvia s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain

Received 27 August 2012; Accepted 8 October 2012

Academic Editors: T. Mimura, M. Nakazawa, and L. Pierro

Copyright © 2012 F. Lopez-Lopez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Purpose. To evaluate efficacy of intravitreal triamcinolone (IVT) and bevacizumab (IVB) as adjunctive treatments to panretinal photocoagulation (PRP) in proliferative diabetic retinopathy (PDR). Methods. In 60 eyes of 45 patients with PDR, PRP (PRP group), PRP with IVT (IVT group), or PRP with IVB (IVB group) was performed. Regression of new vessels (NV), changes in best-corrected visual acuity (BCVA), central macular thickness (CMT), and contrast sensitivity at 1,2, and 6 months were evaluated. Results. Initial mean numbers of active NV and BCVA were 3.45 and 67.35 in the PRP group, 4.35 and 76.65 in the IVT group, and 4.79 and 75.53 in the IVB group. At the 6-month follow-up, numbers of active NV were 2.5 ( ), 1.11 ( ), and 1.11 ( ), and there was a mean loss of 2,6 ( ), 3.9 ( ), and 0.9 letters ( ) in the PRP, IVT, and IVB groups, respectively. Changes in CMT in the PRP and IVT groups were not significant, but significantly increased in the IVB group ( ). Contrast sensitivity remained stable in PRP and IVB groups and slightly decreased in IVT group. Conclusions. Adjunctive use of both triamcinolone and bevacizumab with PRP lead to a greater reduction of active NV than PRP alone in PDR, although no differences were seen between the two of them.